| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 501.4 | 492.9 |
| Profit before tax | 65.0 | 87.8 |
| Net income | 47.0 | 71.7 |
| EPS (diluted, $ a share) | $0.59 | $0.84 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | -34.5% |
|---|---|
| Revenue, year on year | +1.7% |
| Operating margin | 13.0% |
10-Q filed with the SEC, NYSE: MD. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Pediatrix Medical Group, Inc.: key numbers
- Share price
- $31.13Close, Nov 17
- Market cap
- $2.43B
- Shares outstanding
- 78.12MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Services-HospitalsSIC 8060
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Pediatrix Medical Group, Inc.
All →Pediatrix Medical Group Financial Results
Pediatrix Medical Group reported Q3 2026 net revenue of $501.4 million and net income of $47 million, or $0.59 per share. The results were driven by a 1.7% increase in net revenue reflecting growth in both same-unit and non-same unit activity, alongside a favorable shift in payor mix.
- Term
- Q3 2026
“We are pleased with our results this quarter, driven by both volume and pricing performing ahead of our expectations. We continue to push operating efficiency paired with sector leading care quality, while considering high-value opportunities in adjacent businesses, as they arise.”
Mark S. Ordan, Chief Executive Officer